Pila Pharma AB (”Pila Pharma” or ”the Company”) published its interim report for the first half year of 2026 on August 27, 2026. Below are a few points we have chosen to highlight in connection with the report:
- Clinical development in obesity can now be initiated: the approval of PP-CT04 constitutes the gate that had to be passed for upcoming value drivers to become results driven rather than preparatory.
- The timeline is assessed to be intact: a study start in 2026 is in line with Analyst Group’s previous estimates, where Part 1 is expected to be completed around the turn of the year 2026/2027.
- The dose finding component has relevance beyond the obesity track: a favorable outcome in Part 1 is expected to facilitate continued work in both type 2 diabetes and erythromelalgia.
- The capital requirement remains for the efficacy part: the cash position of SEK 13.4m is assessed to cover Part 1, while Part 2 and the parallel studies depend on additional financing.
Approved Study in Obesity Moves the Company from Preparation to Execution
Pila Pharma announced on August 18, 2026, that regulatory approval had been obtained for PP-CT04, a two part, randomized, double blind and placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in people living with obesity over twelve weeks. The study comprises 46 participants and applies individual dose escalation from 4 mg up to a maximum of 16 mg twice daily over up to four weeks, after which each participant continues at their highest tolerated dose during an eight-week maintenance period.
Part 1 consists of an initial safety cohort of eight participants, while Part 2 comprises the remaining 38 participants and may commence following a favorable safety recommendation. Analyst Group views the approval as the gate that had to be passed for continued value creation to be driven by clinical results, as the period since the summer of 2025 has essentially consisted of preclinical work, selection of contract research organizations and regulatory preparation. Part 1 is, according to Analyst Group’s assessment, expected to be completed around the turn of the year 2026/2027, after which the efficacy part may be initiated. In our analysis of Pila Pharma, we have assumed a study start in obesity relating to a Phase Ib/Phase IIa study in 2026, expected to run for approximately one year, and the regulatory approval for PP-CT04 means that this timeline is assessed to be intact.
Analyst Group further assesses that the value of the dose finding component extends beyond the indication the study formally concerns. The approval relates to obesity, while the previously planned study in obesity and type 2 diabetes and the planned study in erythromelalgia constitute separate trials requiring their own approvals and access to the necessary funding. The dose, safety and pharmacokinetic information generated is, however, largely tied to the compound rather than to the indication, and a favorable outcome in Part 1 is therefore expected to facilitate continued work across both tracks, where the Company holds orphan drug designation from the FDA in erythromelalgia. That tolerability may differ between patient groups means at the same time that an established dose level cannot automatically be transferred between indications. Even with that reservation, Part 1 is assessed to constitute a value driver for the development portfolio as a whole, strengthening the conditions for the broader data package underpinning future partnership discussions.
Part 1 of the Study is Assessed to be Financed by Existing Cash
Operating expenses amounted to SEK 3.9m (4.9) in H1-26, demonstrating continued solid cost control and in line with our assessment that ongoing fixed costs amount to approximately SEK 7m annually.
Total cash, including the subsidiary’s cash of SEK 10.1m, amounted to SEK 13.4m at the end of June 2026, which compares to SEK 19.3m at the end of 2025, meaning cash decreased by SEK 5.9m during the period, while TO2 strengthened the cash position by approximately SEK 5.3m in February, whereby total cash consumption during the half year amounted to SEK 11.2m. The cash consumption is assessed to reflect reduced study activity during the half year, where the Company primarily focused on the work of submitting the application for the clinical study PP-CT04 in H1-26, although the period is also assumed to include certain costs for the preclinical study concluded in January 2026. Cash consumption is somewhat below our estimates in our most recent equity research report, in which we estimated, however, that parallel type 2 diabetes and obesity studies would be initiated simultaneously in 2026, which is no longer expected, and we intend to review our estimates in a forthcoming analysis update. Existing liquid assets are nevertheless assessed to be sufficient to finance Part 1 of PP-CT04, while Part 2 depends on additional financing.
Market Developments During the Period are Assessed to Strengthen Demand for Alternative Mechanisms
The market for obesity drugs has developed rapidly during the first half of 2026. Oral semaglutide was launched in the US in January and the FDA approved Eli Lilly’s orforglipron on April 1, whereby two tablet based GLP-1 products are now available on the US market. Early sales data indicate that the oral administration form broadens the market rather than replacing injectable treatments, as the majority of volume consists of patients not previously treated with GLP-1. Pricing has at the same time changed structurally following the pricing agreements reached between US authorities and the two dominant players Novo Nordisk and Eli Lilly, where oral treatments are now priced in the range of USD 149 to 399 per month depending on dose and sales channel, while the price toward Medicare amounts to approximately USD 245 per month.
Analyst Group assesses that the development carries a twofold implication for Pila Pharma. On the one hand, the reference level for clinical efficacy has risen, as several oral candidates have reported weight loss during the year at levels previously associated with injectable treatments, while pricing is pressured structurally. On the other hand, the premise underpinning the Company’s strategy is confirmed, namely that administration form and accessibility are decisive for how large a share of the patient population is reached in practice, and that the market is fragmenting toward several parallel mechanisms of action as tolerability and the composition of weight loss gain importance.
Going forward, Analyst Group assesses that XEN-D0501’s competitiveness will primarily need to be carried by tolerability, cardiometabolic effects and the potential as a combination component, rather than solely by weight loss in absolute terms, which is in line with PP-CT04 being designed around tolerability at higher doses and longer treatment duration. That licensing activity in obesity remains high, where committed deal values during the first quarter of the year exceeded full year 2025, indicates that interest in differentiated assets persists, which is assessed to be central to realizing the value of the Company’s development portfolio.
Furthermore, Eli Lilly has taken legal action against a number of clinics and resellers marketing copies of the company’s development candidate retatrutide, an injectable treatment that in a Phase III study demonstrated weight loss averaging close to 30% of body weight, despite the candidate not yet having been approved for weight management. That a gray market emerges for a treatment not yet approved is assessed by Analyst Group to illustrate the unmet demand within the indication. At the same time, the development means the bar for clinical efficacy continues to rise. It should be noted here, however, that an oral, non incretin based tablet competes on partly different parameters than a weekly injection, such as administration method, side effect profile and the possibility of combination treatment, and Analyst Group therefore considers that market developments on balance strengthen rather than weaken the rationale for treatment alternatives with a different mechanism of action.
In summary, the regulatory approval of PP-CT04 constitutes the single most important announcement of the period, as the Company thereby moves from preparation to clinical execution. Analyst Group views the approval as a central value driver in the case, partly as upcoming triggers become more results driven, partly as the dose finding component is expected to create better conditions for continued development across further indications for the Company’s drug candidate. With total cash of SEK 13.4m, Part 1 is assessed to be feasible with existing funds, while Part 2 and the parallel studies require additional financing, and capital raising is therefore assessed to constitute the next material milestone alongside the study outcome. In the coming analysis update, Analyst Group intends to review the assumptions regarding timeline, financing and deal value, in light of both the newly approved study and market developments in obesity.
Analyst Group will return with an updated equity research report on Pila Pharma.